Healthcare supplies sales and organic growth around the world lifted 3M earnings in the third quarter.
Jim Cramer weighs in on how to adjust your fantasy football team for week eight of the NFL season.
U.S. Stocks are higher at the Opening Bell with the Dow Industrials up more than 100 points.
Eli Lilly lost exclusivity in high profile drugs like Cymbalta and Evista and generic competition brought down the volume of medications doctors prescribed.
PetSmart is back in the spotlight, even though it won't report earnings until November 23.
Semiconductor stocks look undervalued.
There's only one I can think of for Coke, and I am unsure on IBM.
Investors can learn from Buffett's recent misstep with Tesco.
Cramer prefers Celgene over Kite Pharma, General Electric over Babcock & Wilcox and sees a red flag over Ellington Financial.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to find the stocks he and Stephanie Link think could be HUGE winners. Click here to see them for FREE.
Here's a look at how to trade some of the biggest stocks on Wall Street.
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
These stocks rising on unusual volume are within range of triggering breakout trades.
Here's how to trade some of the most active tech stocks on the market right now.
Here's how to trade some of the most active stocks on the market today, including Alibaba and Boston Scientific
Passengers complain about cramped flights but are willing to sacrifice even more legroom for a cheaper ticket.
The Social Security Administration has announced that the monthly Social Security benefit will give retirees a much needed boost.
Retail marijuana industry sales could reach $21 billion by 2020. But the marijuana boom hasn't yet achieved the high industry insiders had hoped for.
Ever wanted to sack it all in and move West? There are a number of logistical issues that present themselves.
Go here to get in the spirit of spookiness.
Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 press release.
But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
Chairman Richard Broadbent resigns after accounting errors led to a major profit overstatement.
Sources said lenders led by private equity firms Littlejohn & Co. and New Mountain Capital will swap debt for equity and provide as much as $43 million in post-petition financing.
The two buyout firms will hold equal ownership interests in the rental housing guide publisher.
Jim Cramer and Jill Malandrino look at a several retail stocks, identifying potential out and underperformers and some M&A ideas.
I can't remember a time when so many big brands stumbled.
Action Alerts PLUS has been buying into it.
Yelp shares plunged Thursday after the social reviews and delivery service company gave a fourth-quarter outlook sharply lower than forecast, causing investors to worry about the c...
Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 pre...
The stock market has come roaring back this week after last week's scary selloff, but investor appetite for initial public offerings has yet to recover.
Five airlines reports record third quarters and United posts its best quarter ever. But United's advance bookings decline.